Industry News

Multipurpose Femtosecond Laser

Ziemer have announced their newest femtosecond laser, the FEMTO Z8 NEO, successor to the multipurpose femtosecond laser LDV Z8. Featuring a new laser source and monitoring system to optimise precision and reliability, the new laser enhances usability with a slim handpiece and improved docking system to ensure perfect eye fit for even the most challenging cases. New software provides more intuitive user guidance, improving workflow, and offers new surgical applications. “The new FEMTO Z8 NEO continues a long-standing Ziemer tradition of raising the bar for ourselves and the entire ophthalmic industry,” explains Frank Ziemer, CEO and President of Ziemer Ophthalmic Systems.

ALL-IN-ONE SURGERY PLATFORM

Oertli have launched the newest generation of OS 4, their retina, glaucoma, and cataract surgery platform. Two LED light sources increase power by 45% while an extended control range provides for more applications, as well as high-resolution contrast viewing. The integrated endo laser offers a fully automated user protection filter. A multifunctional pedal with over 100 setting options offers precise control according to each surgeon’s preference. The unique three-pump fluidics system maintains control in a wide range of surgical scenarios. “The Oertil OS 4 is the only platform worldwide which serves three ophthalmic key disciplines in one device,” said Thomas Bossard, co-owner, board member, and head of marketing and sales.

NEWS IN BRIEF

PRESBYOPIC IOLS

OPHTEC have introduced a new pair of presbyopia-correcting lens, the Precizon Toric and Precizon Presbyopic IOL. For the correction of presbyopia, the lenses have multiple-segment optics with patented Continuous Transitional Focus for a smooth transition between the far and near segments, delivering excellent intermediate vision. A Transitional Conic Toric optic makes the lenses tolerant of misalignment by calculating different conic constants not only on the horizontal and vertical axis, but also between 0 and 90 degrees.

SUBRETINAL INJECTOR APPROVED

MedOne have received 510(k) pre-market approval from the US Food and Drug Administration (FDA) for their MicroDose Injector. The device adapts vitrectomy console viscous fluid injection sets to use a 1mL syringe, enabling full surgeon control for administering subretinal injections with minimal fluid loss. It can be attached to the VFI tubing set from Constellation®, Stellaris®, and EVA® systems.

CELL THERAPY ALLIANCE

BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics have entered into a strategic alliance to discover and develop off-the-shelf induced pluripotent stem (iPS) cell technologies for ocular diseases. “We believe deeply that authentic cells are the breakthrough approach needed to treat degenerative retinal diseases like AMD and IRDs,” said Emile Nuwaysir PhD, president and CEO of BlueRock, a wholly owned subsidiary of Bayer. “Bringing together the expertise of our partners with Opsis Therapeutics’ innovation in generating authentic iPS cell-derived human retinal cells, we have the potential to develop life-changing treatments for patients and their families,” said Nick Manusos, CEO of Opsis.